⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VSTM News
Verastem, Inc.
Form 8-K
sec.gov
VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
businesswire.com
VSTM
Visiting Media Appoints Tom Cutsforth as Chief Financial Officer to Drive Global Scale
globenewswire.com
VSTM
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
businesswire.com
VSTM
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
businesswire.com
VSTM
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
businesswire.com
VSTM
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
prnewswire.com
ONCY
RNXT
VSTM
PFE
CATX
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
VSTM
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
businesswire.com
VSTM
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
businesswire.com
VSTM